Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Exclusive News
Why Boston Scientific's Big Dip Could Be a Bigger OpportunitySubmitted by Nathan Reiff. Posted: 3/24/2026. 
Key Points
- Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) has gotten off to a rough start this year: shares are down about 26% year-to-date and roughly a third over the past year. But investors who dig into the healthcare company's fundamentals will find some encouraging results, including adjusted earnings per share (EPS) of $0.80 for the most recent quarter, $0.02 above consensus. A closer look at Boston Scientific's earnings shows strength in several areas—most notably its electrophysiology (EP) segment and Watchman products, which have grown rapidly and appear positioned to continue performing. The company is also expected to report results from its Champion-AF trial by the end of March, which could materially expand the product's addressable patient base. Those factors may tempt investors to buy the dip in BSX, but it's important to remember why shares fell and what risks remain. Is the Boston Scientific Dip Justified?
Twenty-one banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - are competing to underwrite the SpaceX IPO, internally codenamed 'Project Apex.' At a $1.75 trillion valuation, it would be the largest IPO in Wall Street history.
Studies show 95% of total profits are made before a company goes public. Dr. Mark Skousen has identified a little-known fund run by a Wall Street legend who already turned Tesla into a 30-bagger - and is now betting big on SpaceX ahead of an expected June IPO. Discover how to claim your stake in SpaceX before the IPO hits
Shares of BSX sold off after the February earnings release despite revenue rising roughly 16% year over year and adjusted EPS beating estimates. Free cash flow improved markedly as well, increasing about 38% year over year to approximately $3.7 billion. The selloff appears to reflect disappointment with management's 2026 organic revenue guidance of 10% to 11% year-over-year growth—well below 2025's roughly 20% full-year growth. Part of the slowdown is attributable to the near-term effects of discontinuing certain Axios catheter products and other lines at the start of the year. Management expects that action to shave about 150 basis points off early-2026 growth. Still, much of Boston Scientific's business remains intact and expanding. The company is forecasting another year of free cash flow growth—about $4.2 billion in 2026—along with continued operating-margin expansion and other improving metrics. The Champion Trial Could Be a Catalyst for ReversalOne potential catalyst to reverse the stock's slide is the Champion trial, which compares the Watchman stroke-reduction implant with oral anticoagulants. Investors should watch these results closely, because a positive outcome could expand the addressable patient pool for Watchman to as many as 20 million—roughly four times the current estimate. If the trial is favorable, the impact could be significant over multiple years, expanding the global addressable patient population and driving sales growth. Another potential growth driver is Boston Scientific's planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra would give Boston Scientific an entry into the mechanical thrombectomy market, where it currently has no presence. The $14.5 billion deal is financed in part by a $6 billion term loan secured in late February. While that adds near-term financial pressure, Boston Scientific's rising free cash flow and solid fundamentals may mitigate investor concern. Risks and Analyst Perspectives Are Worth Keeping in MindA negative Champion trial result would be a major risk to the company's growth thesis. It could undermine expectations for accelerating Watchman sales and make the 2026 organic revenue guidance of 10% to 11% harder to achieve. Conversely, Wall Street remains broadly bullish on Boston Scientific: of 25 analyst ratings, 23 are Buys and two are Holds. Several firms—including Stifel Nicolaus, Jefferies, and Truist Financial—reissued Buy ratings in March, though some have trimmed their price targets while keeping Buy calls. Overall, the consensus price target of $106.27 implies more than 50% upside from current levels, suggesting analysts see considerable potential if catalysts play out as hoped. |
0 Response to "We're excited to have you on board"
Post a Comment